Fermer le menu

 

Member of Lyonbiopole

 

90% of cancer deaths are related to drug resistance which undercuts the efficacy of anti-cancer drugs like inhibitors of MAPK signaling, a pathway hyperactivated in 40% cancers. Another limitation of MAPK Inhibitors is their inability to cure rare diseases caused by MAPK-activating mutations.

To overcome these limitations, TheraPPI develop drugs inducing signal dysregulation instead of signal inhibition. Our two first programs target a MAPK protein interaction discovered by the founder team.

 

Application market: Immune, AutoIm & Inflam. diseases, Oncology, Rare disease

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Small Molecules

Created on jan. 11th, 2023 - 2 employees

 

Address

28 Rue Laennec
CENTRE LEON BERARD
69008 LYON

 

Contacts

Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.